Wednesday, April 15

Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease

Signal observed that adjunctive prednisolone in primary Kawasaki disease treatment did not reduce coronary artery lesions at 1 month (16.0% vs 13.8% with standard care alone). Evidence suggests prednisolone may reduce rescue therapy requirements (4.6% vs 10.1%) and fever duration, though coronary outcomes remained similar between groups at 3 months. Worth noting this large randomized trial (n=3208) found no significant difference in primary coronary endpoints despite some secondary benefits.

(Funded by the Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences and the National Natural Science Foundation of China; ClinicalTrials.gov number, NCT04078568.).

Relevance: Randomized controlled trial directly evaluating prednisolone in primary treatment of Kawasaki disease (dx-kawasaki). Examines coronary-artery lesions and rescue therapy outcomes, directly relevant to profile diagnosis and clinical outcomes of interest.

Clinical Study of Atorvastatin in the Treatment of Acute Kawasaki Disease Complicated With Coronary Artery Abnormalities in Children

Evidence suggests investigation of atorvastatin as adjunctive therapy for acute Kawasaki disease with coronary abnormalities is underway in pediatric patients. Worth noting this represents exploration of statin therapy beyond traditional anti-inflammatory approaches for coronary sequelae management. The study targeting children with existing coronary involvement indicates focus on secondary prevention strategies.

Relevance: Clinical trial investigating atorvastatin in acute Kawasaki disease (dx-kawasaki) with coronary artery abnormalities in children. Directly relevant to profile diagnosis in pediatric population and coronary sequelae outcomes.